Drug Resistance Analysis of ESBLs-Producing Enterobacteriaceae in Lower Respiratory Tract Infections

Objective To analyze the drug resistance of enterobacteriaceae producing extended spectrum β-lactamases (ESBLs) in lower respiratory tracts infection, in order to facilitate the rational use of antimicrobials in clinic. Methods Statistical analysis was made on the distribution and drug resistance of enterobacteriaceae isolated from cultures of phlegm samples collected in Kaiping in 2012. Results 236 strains of enterobacteriaceae bacteria were detected. Among the strains, 43.6% were Klebsiella pneumonia, 21.3% were escherichia coli and 14.8% were Enterobacter cloacae. Positive rates in ESBLs phenotypic confirmatory test were 38.8% , 64.0% and 9.4% respectively. Resistant rate to carbapenems of ESBLs-producing Enterobacteriaceae was the lowest (lower than 12.5%); resistant rates to amikacin, piperacillin/tazobactam and cefoxitin were comparatively higher, which were below 22.7%, 36.4% and 40.9% respectively; resistant rates to ceftriaxone, ceftazidime and cefepime were all higher than 90%. Conclusions Lower respiratory tract infection caused by ESBLs-producing enterobacteriaceae is common, and carbapenems, amikacin and piperacillin/tazobactam are the antimicrobials to which the bacteria are more sensitive at present.